We've learned a lot about Prior Covid ("Natural Immunity") over the past year, but the US/CDC continues to negate the abundant evidence for it providing any protection erictopol.substack.com/p/ground-truth… w/links
And there's substantial new data, I'll review🧵here /1
Last week, the large J&J 1- shot, placebo-controlled trial w/ >2,000 participants who had Prior Covid published @NEJM
Vaccine effectiveness vs moderate/severe disease
Prior Covid 90%
J&J Vaccine 56%
Yet 1-shot J&J vaccine = "fully vaccinated" @CDCgov
Nothing for Prior Covid /2
Neutralizing antibodies after Prior Covid are present out to 16 months in 214 people (graph)
And another study showing persistence of memory B cells at 15 months /3
Over 7,000 UK health care workers with Prior Covid and assessment of IgG antibodies that were anticipated to last 1.5 to 2 years /4
The January 2022 CDC MMWR for California and New York State showed remarkable protection of Prior Covid, unvaccinated vs hospitalization, during the Delta wave /5
The new UK study, November 2021 to January 2022, the largest comparison of Omicron and Delta for hospitalizations and deaths, among 1.5 M people
Prior Covid, unvaccinated, hazard ratio, 95% CI
Hospitalization 0.55 (0.45, 0.63)
Death 0.18 (0.06, 0.57) /6
The protection afforded by Prior Covid was substantially reduced with Omicron, as evidenced by the jump in reinfection in the UK (previously quite rare) /7
And the drop in vaccine effectiveness vs symptomatic infection in Qatar, as published this week, from ~90% (prior variants) to 56% (Omicron) /8
All studies for Prior Covid have issues w/r to survival bias (people who died not included), heterogeneity of antibody,cellular immune response levels and their durability.
Getting Covid obviously doesn't protect #LongCovid, unlike vaccines which have shown protective benefit /9
There is unequivocal synergy of hybrid immunity (combined Prior Covid and 1 or more vaccine doses) in more than 25 studies pre-Omicron, and several with Omicron, for the augmented immune response /10
The CDC should reboot its "vaccination card" to a digital "immunity certificate" and give credit to confirmed Prior Covid, that is equivalent to at least a 1-dose vaccine /11
Vaccine mandates, without long overdue recognition of Prior Covid's protection, unnecessarily fuels divisiveness.
The US is only 64% "fully vaccinated" compared w/ many countries at 80%+. Recognition of Prior Covid can help build our immunity wall, which should be the priority
I meant to add this report (it's in the full post) from >52,000 health care workers at Cleveland Clinic health system which showed lack of symptomatic infections in the Prior Covid, unvaccinated group, at 1-year follow up, through the Delta phase
• • •
Missing some Tweet in this thread? You can try to
force a refresh
A dedicated issue of @ScienceTM on #LongCovid
—Sex-specific differences, with perspective by @VirusesImmunity and @SilvaJ_C
—Insights for therapies @AndreaCoxMDPhD
—Deconvoluting "Osler's Web" @MichaelPelusoMD @DeeksSteven @DrMaureenHanson @SaydahSharon
—+RECOVER Trial, Lyme disease
An elegant @Nature study by @AkassoglouLab has illuminated our understanding of the role of fibrin (component of blood clots), #SARSCoV2, and brain inflammation in Covid and #LongCovid.
This discovery and more in the new Ground Truths podcast, with transcript, key figures (such as as the one below) and citations. Open-access. Link in my profile.
A clip from our conversation. Unknowingly, @AkassoglouLab was gearing up for understanding this complex pathophysiology for many years before Covid hit
For treatment, it's not just as simple as preventing fibrin clots. It's isolating the pro-inflammatory action of fibrin, targeted by the antibody
Covid and increased risk of major adverse cardiovascular events (MACE) 3-years out
2-fold increased for any severity of Covid
~4-fold increase for Covid requiring hospitalization
"a coronary artery disease equivalent"
interaction with non-O blood types
@uk_biobankahajournals.org/doi/10.1161/AT…
"A major finding from our analyses was that the risk
of MACE among the subset of hospitalized COVID-
19 cases without known CVD (ie, primary prevention
patients) was comparable to (or even slightly higher than) the risk in patients with CVD, PAD, or diabetes but without COVID-19."
"one of the first examples of a gene-pathogen exposure interaction for thrombotic events"
I think it's the first one documented, likely others to be unraveled
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)